SCHEMBL3773673

SCHEMBL3773673

O=C(CN1CCN(c2ccc(C(F)(F)F)cn2)CC1)N1CCN(C2CCCC2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.54
HPGD P15428 1/20 0.54
HSD11B1 P28845 4/20 0.54
MAPT P10636 3/20 0.53
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NPSR1 Q6W5P4 1/20 0.53
KDM4E B2RXH2 4/20 0.52
LMNA P02545 3/20 0.52
ABL1 P00519 1/20 0.52
POLB P06746 2/20 0.52
THRB P10828 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
HTT P42858 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
IDE P14735 1/20 0.49
CHRM2 P08172 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3777238 0.99 SMN1; SMN2 (0.53) SMN1; SMN2HPGDHSD11B1MAPTALDH1A1
SCHEMBL3771336 0.98 SMN1; SMN2 (0.54) SMN1; SMN2HPGDHSD11B1MAPTALDH1A1
SCHEMBL3769780 0.86 ALDH1A1 (0.51) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL3764966 0.86 SMN1; SMN2 (0.47) SMN1; SMN2HPGDHSD11B1MAPTALDH1A1
SCHEMBL3763137 0.85 ME2 (0.55) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL3765979 0.84 SMN1; SMN2 (0.49) SMN1; SMN2HPGDMAPTALDH1A1MEN1
SCHEMBL3967944 0.84 KDM4E (0.58) SMN1; SMN2HPGDMAPTALDH1A1MEN1
SCHEMBL3769215 0.84 ME2 (0.54) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL3771430 0.84 SMN1; SMN2 (0.48) SMN1; SMN2HPGDMAPTALDH1A1MEN1
SCHEMBL3768152 0.83 HRH3 (0.63) SMN1; SMN2MAPTALDH1A1NPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 SMN1; SMN2 4282/4885HPGD 377/4885HSD11B1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.